Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma 1Rhabdoid Tumor 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1Blast Crisis 1

Interventions

Doxorubicin 5brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Nivolumab 2Ifosfamide 2Etoposide 2AZD 6244 2thymoglobulin 1tazemetostat 1sotigalimab 1selinexor 1romidepsin 1perifosine 1pembrolizumab 1pazopanib 1lorvotuzumab mertansine 1fludarabine phosphate 1exatecan 1decitabine and cedazuridine drug combination 1Trabectedin 1Thiotepa 1Temozolomide 1Tacrolimus 1Sunitinib 1Stem Cell Transplantation 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibrosarcoma × Razoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡